On March 11, 2021 iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), reported that between February 1, 2021 and March 12, 2021, 20,280,000 warrants of the Company were exercised for common shares in the capital of the Company resulting in proceeds to the Company of $1,301,200.00 (Press release, iCo Therapeutics, MAR 11, 2021, View Source [SID1234576565]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

William Jarosz, the Chief Executive Officer of iCo commented, "We deeply appreciate this show of support from our warrant holders. These funds will help us more rapidly advance strategic opportunities we’ve been pursuing."